Clinical Practice Guidelines: Pre-malignant Lesions of Anal Area (1/2)

Patients with dysplasia should be followed at regular intervals (variety of methods) 2B

Screening with Anal Pap can be considered in high risk pts (but not for universal screening) 2B

HRA can be considered for screening when performed by someone with appropriate training (2B)

Ablative treatment (with conventional anoscopy or HRA) is appropriate for HSIL (2B)

Topical agents are options for treatment of LSIL or HSIL (2B)

Vaccination against HPV (age <26) for primary prevention is recommended (2A)